Contact
- Contact Us
- Submit a Press Release
- Submit a Coin
- Submit an Exchange
- Submit a Wallet
- Submit a Company
- Advertise
- Linktree
EncrypGen, also known by its ticker DNA, is a blockchain-based platform that aims to challenge the monopoly held by big testing companies over genomic data. These companies generate substantial revenue by selling individuals’ genetic information. EncrypGen’s Gene-Chain provides an alternative approach by allowing individuals to become sellers, giving them control and the opportunity to profit from their data.
To participate, individuals can upload their raw DNA data file and create a Gene-Chain profile. EncrypGen ensures privacy by de-identifying the data and removing sensitive information such as names and email addresses. Data buyers can then search for suitable profiles on the Gene-Chain and purchase de-identified genomic data using DNA tokens.
DNA tokens, an ERC-20-based cryptocurrency, can be obtained from various crypto exchanges worldwide. These tokens are used for purchasing genomic data and can be exchanged for Bitcoin, Ethereum, and other altcoins. EncrypGen’s vision is to create a marketplace within the Gene-Chain where individuals can buy DNA data and access other DNA products and health-related services.
Total Commits | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Branches | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Releases | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Watchers | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Forks |
Stay in the loop. Subscribe for updates.
Are you looking to advertise? We offer press release publications, display banners, featured listings and more.
Contact us for questions, submit a PR or request our media kit.
Contact
Advertise
Are you looking to advertise? We offer press release publications, display banners, featured listings and more.
Contact us for questions, submit a PR or request our media kit.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis